Treatment regimens
| Regimen . | Trial no. . | |
|---|---|---|
| MCL1: 1996-2000 . | MCL2: 2000-2006 . | |
| Induction | Maxi-CHOP21* × 3 | Maxi-CHOP21 × 3 alternating with HD-cytarabine × 2† |
| Stem cell mobilization | Maxi-CHOP21 | Rituximab day 1 of each cycle‡ |
| HD-cytarabine | ||
| Stem cell purging | In vitro: CD34+ cell selection when possible | In vivo: rituximab × 2 (days 1 and 9 of the HD-cytarabine) |
| Consolidation§ | Allowed (1-2 series) | Allowed (1-2 series) |
| High-dose therapy | BEAM¶/BEAC‖ | BEAM: 90 patients |
| BEAC 55 patients | ||
| Preemptive treatment at molecular relapse | No | Rituximab 375 mg/m2 weekly × 4 |
| Regimen . | Trial no. . | |
|---|---|---|
| MCL1: 1996-2000 . | MCL2: 2000-2006 . | |
| Induction | Maxi-CHOP21* × 3 | Maxi-CHOP21 × 3 alternating with HD-cytarabine × 2† |
| Stem cell mobilization | Maxi-CHOP21 | Rituximab day 1 of each cycle‡ |
| HD-cytarabine | ||
| Stem cell purging | In vitro: CD34+ cell selection when possible | In vivo: rituximab × 2 (days 1 and 9 of the HD-cytarabine) |
| Consolidation§ | Allowed (1-2 series) | Allowed (1-2 series) |
| High-dose therapy | BEAM¶/BEAC‖ | BEAM: 90 patients |
| BEAC 55 patients | ||
| Preemptive treatment at molecular relapse | No | Rituximab 375 mg/m2 weekly × 4 |
Maxi-CHOP-21: cyclophosphamide 1200 mg/m2 intravenously, doxorubicin 75 mg/m2 intravenously, vincristine 2 mg total intravenously day 1; prednisone 100 mg days 1-5 orally.
Cytarabine: 3 g/m2 (3-hour infusion intravenously) every 12 hours for a total of 4 doses; patients older than 60 years, cytarabine 2 g/m2.
Rituximab 375 mg/m2 intravenously on day 1 of each cycle from cycle 4.
In case of delay in the transplant unit, 1 extra immunochemotherapy cycle of Maxi-CHOP21, HD-cytarabine, or both were allowed.
BEAM: BCNU 300 mg/m2 day 1, etoposide 100 mg/m2 × 2 days 2-5, cytarabine 400 mg/m2 days 2-5, melphalan 140 mg/m2 day 6, all intravenously.
BEAC: As BEAM, cyclophosphamide 1.5 g/m2 days 2-5 instead of melphalan.